Log in

NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

$9.84
+0.34 (+3.58 %)
(As of 12/8/2019 05:06 AM ET)
Today's Range
$9.45
Now: $9.84
$9.84
50-Day Range
$7.66
MA: $8.39
$9.84
52-Week Range
$6.22
Now: $9.84
$13.25
Volume1.34 million shs
Average Volume879,570 shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$2.65 per share

Profitability

Net Income$-120,010,000.00

Miscellaneous

Employees235
Market Cap$1.11 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.08. During the same quarter in the previous year, the business earned ($0.24) EPS. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

5 Wall Street analysts have issued 1-year price targets for Spectrum Pharmaceuticals' stock. Their forecasts range from $18.00 to $40.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $23.40 in the next twelve months. This suggests a possible upside of 137.8% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Spectrum Pharma is progressing well with its lead pipeline candidate, Rolontis and a regulatory application for the same is expected to be filed soon. An approval will boost the prospects of the company. Development of poziotinib is progressing well, including in a phase II pivotal study in second-line lung cancer. Moreover, the sale of its marketed products is helping Spectrum to focus on and support the development of its pipeline candidates. However, Spectrum faced regulatory setbacks including withdrawal of regulatory application for Rolontis seeking approval for neutropenia in the United States. Additional regulatory/development setbacks, especially related to Rolontis, could affect the stock. Loss estimates  have narrowed ahead of Q3 earnings. The company has a mixed record of earnings surprises in the recent quarters." (10/17/2019)
  • 2. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News coverage about SPPI stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Spectrum Pharmaceuticals.

Are investors shorting Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 8,450,000 shares, a decline of 8.7% from the October 31st total of 9,260,000 shares. Based on an average daily trading volume, of 779,300 shares, the short-interest ratio is currently 10.8 days. Approximately 8.7% of the shares of the company are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Opko Health (OPK), TG Therapeutics (TGTX), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE) and Clovis Oncology (CLVS).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.85%), Voya Investment Management LLC (0.92%), Sargent Investment Group LLC (0.47%), Rhumbline Advisers (0.30%), California Public Employees Retirement System (0.20%) and California State Teachers Retirement System (0.15%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Voloridge Investment Management LLC and Congress Asset Management Co. MA. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Russell Investments Group Ltd., California Public Employees Retirement System, Squarepoint Ops LLC, Sargent Investment Group LLC, State of Alaska Department of Revenue, Mackay Shields LLC and Rhumbline Advisers. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $9.84.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $1.11 billion and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  739
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Accumulation/Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel